Search

Displaying results 6451 - 6460 of 10000 in total
  1. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

  2. Drug

    Oxybuprocaine

    go.drugbank.com/drugs/DB00892
    ApprovedInvestigational

    Oxybuprocaine (also known as Benoxinate) is a local anesthetic, which is used especially in ophthalmology and otolaryngology.

    Synonyms: 4-Amino-3-n-butoxy-benzoesäure-diäthylaminoäthylesterProducts: Benoxinat 1% - Lösung zur Anästhesie in der Oto-Rhino-Laryngologie
  3. Drug

    Ferric subsulfate

    go.drugbank.com/drugs/DB13885
    Approved

    Ferric subsulfate is a stypic or hemostatic agent that causes agglutination of surface proteins resulting in local hemostasis. It has the chemical formula Fe4(OH)2(SO4)5.

  4. Drug

    Fenobam

    go.drugbank.com/drugs/DB12931
    Investigational

    Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance

  5. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning

  6. Drug

    Biricodar

    go.drugbank.com/drugs/DB04851
    Investigational

    The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).

  7. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  8. Drug

    Human Embryonic Stem Cell-derived M Cell

    go.drugbank.com/drugs/DB15734
    Investigational

    IMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. … However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury

  9. Drug

    Ethanolamine

    go.drugbank.com/drugs/DB03994
    Investigational

    A viscous, hygroscopic amino alcohol with an ammoniacal odor. It is widely distributed in biological tissue and is a component of lecithin.

  10. Drug

    D2C7 immunotoxin

    go.drugbank.com/drugs/DB17540
    Investigational

    D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas). … D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.